Viemed Healthcare (VMD) AI Stock Analysis

• Market Cap: $266.79M
• Dividend Yield: N/A
• Average Volume (3M): 179.20K
• Price to Earnings (P/E): 22.6
• Beta (1Y): 1.03
• Revenue Growth: 19.97%
• EPS Growth: 17.21%
• Country: US
• Employees: 1,222
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Devices
• EPS (TTM): 0.06
• Shares Outstanding: 39,523,790
• 10 Day Avg. Volume: 243,451
• 30 Day Avg. Volume: 179,204
• PEG Ratio: 2.96
• Price to Book (P/B): 1.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 189.52
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 0.28
• Enterprise Value/Gross Profit: 1.80
• Enterprise Value/Ebitda: 1.43
• 1Y Price Target: $15.00
• Price Target Upside: 120.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Viemed Healthcare shows robust financial growth and strategic expansion efforts, reflected in its solid earnings call performance. However, technical indicators suggest caution due to potential short-term pressures. The company's valuation is reasonable given its growth outlook, although improvement in free cash flow management remains crucial.

Viemed Healthcare Business Overview & Revenue Model

Company Description

Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company also leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), percussion vests, oxygen concentrator units, and other small respiratory equipment; and sells and rents DME and patient medical services. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management related solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

How the Company Makes Money

Viemed Healthcare generates revenue by providing respiratory care services and selling or renting durable medical equipment to patients, healthcare providers, and institutions. The company's primary revenue streams include the rental and sale of non-invasive ventilators and other respiratory therapy equipment. Additionally, Viemed earns income from providing ongoing patient care and monitoring services, which are typically reimbursed by Medicare, Medicaid, and private insurance companies. This reimbursement model is crucial to Viemed's revenue, as it ensures a steady cash flow from insurance providers for the equipment and services rendered to patients. Viemed also pursues strategic partnerships with healthcare providers and institutions to expand its service offerings and enhance its market presence.

Viemed Healthcare Financial Statement Overview

Summary

Viemed Healthcare demonstrates strong revenue growth and robust gross profit margins, reflecting effective cost management and business expansion. Despite strong operational efficiency, pressures on net profit margins and declining free cash flow due to increased capital expenditures present challenges.

Income Statement

Viemed Healthcare shows a strong financial performance with consistent revenue growth, increasing from approximately $80.3 million in 2019 to $224.3 million in 2024. The gross profit margin is robust, indicating effective cost management, with a margin of 59.4% in 2024. The company also improved its EBIT and EBITDA margins, reflecting operational efficiency. However, net profit margin has declined from 24% in 2020 to 5% in 2024, suggesting rising costs or other financial pressures affecting net income.

Balance Sheet

The balance sheet indicates a solid financial position with an improving equity base, growing from $43.7 million in 2019 to $131.4 million in 2024. The debt-to-equity ratio is very low at 0.05 in 2024, highlighting prudent financial management. However, the equity ratio has decreased from 72.6% in 2020 to 105.8% in 2024, which suggests a more aggressive leveraging strategy. Despite this, the company remains well-capitalized.

Cash Flow

Viemed's cash flow statements show strong operating cash flows, with a slight decline from $45.2 million in 2023 to $39.1 million in 2024. The free cash flow, however, has been volatile, dropping significantly from $19.1 million in 2023 to $1.3 million in 2024, likely due to increased capital expenditures. The ratio of operating cash flow to net income remains healthy, supporting the company's ability to generate cash from operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
224.26M	183.01M	138.83M	117.06M	131.31M
	Gross Profit
133.20M	112.78M	84.68M	73.41M	80.11M
	EBIT
17.90M	14.33M	8.25M	11.58M	26.78M
	EBITDA
42.31M	36.71M	24.03M	21.84M	30.54M
	Net Income Common Stockholders
11.27M	10.24M	6.22M	9.13M	31.53M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
17.54M	12.84M	16.91M	28.41M	30.98M
	Total Assets
177.07M	154.90M	117.04M	117.96M	112.56M
	Total Debt
6.87M	10.32M	694.00K	6.52M	11.13M
	Net Debt
-10.67M	-2.52M	-16.22M	-21.89M	-19.85M
	Total Liabilities
43.77M	41.00M	19.95M	23.14M	30.87M
	Stockholders Equity
131.39M	113.89M	97.09M	94.82M	81.69M
Cash Flow		Free Cash Flow
1.32M	19.12M	4.85M	2.75M	22.07M
	Operating Cash Flow
39.09M	45.21M	27.75M	22.49M	35.11M
	Investing Cash Flow
-30.70M	-52.11M	-23.98M	-19.75M	-8.41M
	Financing Cash Flow
-3.69M	2.83M	-15.27M	-5.32M	-9.07M

Viemed Healthcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VMD, the sentiment is Negative. The current price of 6.8 is below the 20-day moving average (MA) of 6.92, below the 50-day MA of 7.02, and below the 200-day MA of 7.82, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 47.19 is Neutral, neither overbought nor oversold. The STOCH value of 47.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VMD.

Viemed Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	69 Neutral	$266.79M	22.63	9.79%	―	19.97%	17.21%
TCMD	60 Neutral	$241.78M	15.70	8.12%	―	5.96%	-43.83%
RCEL	55 Neutral	$178.17M	―	-407.50%	―	32.24%	-66.93%
Sector *	52 Neutral	$5.19B	3.04	-44.20%	2.82%	16.59%	-0.39%
SNWV	46 Neutral	$253.08M	―	0.65%	―	61.50%	34.99%
ZIMV	46 Neutral	$244.31M	―	-6.35%	―	-32.70%	94.89%
NNOX	45 Neutral	$349.42M	―	-27.83%	―	13.91%	15.46%

Viemed Healthcare Corporate Events

Viemed Healthcare Announces Acquisition of Lehan Drugs

On May 6, 2025, Viemed Healthcare announced its definitive agreement to acquire Lehan Drugs, Inc., a provider of home medical equipment based in Illinois, for $26 million. This strategic acquisition, expected to close in the third quarter of 2025, aims to diversify Viemed’s product offerings into maternal health and expand its market presence, leveraging Lehan’s established reputation and community engagement in the healthcare sector.

Spark’s Take on VMD Stock

According to Spark, TipRanks’ AI Analyst, VMD is a Outperform.

Viemed Healthcare demonstrates strong financial growth, particularly in revenue and gross margins, but faces challenges with declining net margins and free cash flow volatility. Technical indicators are bearish, hinting at potential short-term pressure. However, the company’s strong guidance and strategic growth plans provide a positive outlook, supporting a balanced overall score.

To see Spark’s full report on VMD stock, click here.

Bruce Greenstein Resigns from Viemed Healthcare Board

On April 14, 2025, Bruce Greenstein resigned from Viemed Healthcare‘s Board of Directors, where he served as Chairman of the Corporate Governance & Nominating Committee and a member of the Audit Committee. His resignation was not due to any disagreements with the company’s operations, policies, or practices, suggesting a smooth transition without immediate operational impacts.

Spark’s Take on VMD Stock

According to Spark, TipRanks’ AI Analyst, VMD is a Outperform.

Viemed Healthcare’s overall score reflects robust financial growth and a positive outlook, tempered by technical indicators suggesting caution and valuation metrics that are moderate. The company’s strategic initiatives and strong market presence support its competitive position, but investors should monitor financial pressures and net margin trends.

To see Spark’s full report on VMD stock, click here.

Viemed Healthcare Highlights Strategic Growth in Presentation

Viemed Healthcare has released an investor presentation outlining its strategic focus and growth trajectory. The company emphasizes its competitive advantage through a high-touch, technology-enabled approach to respiratory care, which has led to significant financial performance and extensive nationwide reach. The presentation highlights the company’s robust growth, driven by both organic and inorganic expansion, and its role as a vital link between patients, providers, and payors, aiming to improve patient outcomes and reduce hospitalizations.